British pharmaceutical giant GlaxoSmithKline plc. will pay $20 million to the U.S. Securities and Exchange Commission to settle charges of bribing Chinese doctors and officials in order to boost sales.

In an order issued last Friday, the SEC found that between 2010 and 2013, employees of GSK’s China-based subsidiary and joint venture funneled hundreds of millions of dollars out of the company’s account to bribe doctors and hospitals and other health care staff in China for increasing purchases and prescriptions of the company’s products.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]